Source: Eur Respir J 2010; 36: 915-924



Rating:

Share or cite this content

Citations should be made in the following way:
Reinmuth N., Thomas M., Meister M., Schnabel P.A., Kreuter M.. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Eur Respir J 2010; 36: 915-924

Member's Comments

No comment yet.

Related content which might interest you: Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 FDG-PET is superior to conventional CT in predicting histologic responses after induction therapy for locally advanced NSCLC Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Is skin toxicity a predictive or prognostic factor in EGFR-inhibition as treatment of advanced NSCLC? Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 How to select good candidates for immunotherapy against thoracic malignancies Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 The prognostic value of the expression of GST-π in response to chemotherapy in cytological and pathological specimens of patients with lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Longitudinal micro-CT-derived biomarkers: the new standard readouts for preclinical evaluation of pulmonary fibrosis and therapy Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019 Chemoprevention and treatment of thoracic malignancies through nutritional agents: an update on pre-clinical studies Source: Annual Congress 2010 - Nutrition and cancer Year: 2010 The comparison of the findings of preoperative PET-CT and surgical pathology in patients with non-small cell lung cancer those with and without induction therapy Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Adjuvant chemotherapy in completely resected non-small cell lung cancer: Frequency of biological markers of predictive value Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 Clinical usefulness of the novel drug sensitivity test for malignancy using pleural effusion Source: Annual Congress 2006 - Lung cancer biology and chemosensitivity Year: 2006